Elias Jabbour
Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Elias Jabbour

Intensive Care Medicine
Office
1407 S County Trl Ste 430A, 
East Greenwich, RI 
Clinical Trials:Currently Recruiting for 3 Trials
9 Years of Experience
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Office
1407 S County Trl Ste 430A, 
East Greenwich, RI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elias Jabbour is an Intensive Care Medicine provider in East Greenwich, Rhode Island. Dr. Jabbour has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Febrile Neutropenia, Pleural Effusion, Lung Metastases, Eosinophilic Asthma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 835 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Internal Medicine in RI
Hospital Affiliations
South County Hospital Inc
Kent County Memorial Hospital
The Miriam Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Office
1407 S County Trl Ste 430A, East Greenwich, RI 02818
Other Locations
Kent Hospital
455 Toll Gate Rd, Warwick, RI 02886

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Inotuzumab, 6-Mercaptopurine, Methotrexate, Prednisone, Rituximab, Vincristine
Study Phase: Phase 1/Phase 2
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Recruiting
Publish Date: November 10, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Cytarabine, Methotrexate, Ponatinib
Study Phase: Phase 2
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Enrollment Status: Recruiting
Publish Date: November 06, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, inotuzumab, 6-Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Rituximab, Venetoclax, Vincristine
Study Phase: Phase 1/Phase 2
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Ponatinib, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological, Other
Study Drug: Blinatumomab
Study Phase: Phase 2
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)
Mitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: September 05, 2025
Intervention Type: Drug, Dietary supplement
Study Drugs: Levocarnitine, Vitamin B
Study Phase: Phase 2
Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Biological
Study Drug: Inotuzumab
Study Phase: Phase 2
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Study Phase: Phase 2
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Enrollment Status: Terminated
Publish Date: July 16, 2024
Intervention Type: Biological, Drug, Other
Study Phase: Phase 2
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Etoposide, Ofatumumab, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Enrollment Status: Completed
Publish Date: March 22, 2024
Intervention Type: Drug, Biological
Study Drugs: Clofarabine, Cytarabine, Dexamethasone, Idarubicin, Rituximab, Sorafenib, Sorafenib Tosylate, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: November 04, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegfilgrastim, Rituximab, Vincristine
Study Phase: Phase 2
Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia
Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2021
Intervention Type: Biological, Drug, Other
Study Phase: Phase 2
Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Biological
Study Phase: Phase 2
Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: February 24, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 16 Less Clinical Trials
Similar Doctors
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Kimberly Robinson
Intensive Care Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Kimberly Robinson
Intensive Care Medicine

Massachusetts Cardiology Assoc LLC

159 Union St Ste 102, 
Marlborough, MA 
 (44.7 miles away)
508-481-5000
Languages Spoken:
English
See accepted insurances

Kimberly Robinson is an Intensive Care Medicine provider in Marlborough, Massachusetts. Dr. Robinson is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Asthma in Children, Asthma, and Gastrostomy.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Taro Minami
Intensive Care Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Taro Minami
Intensive Care Medicine

Memorial Hospital Of Rhode Island

111 Brewster St, 
Pawtucket, RI 
 (12.5 miles away)
401-729-2635
Languages Spoken:
English
See accepted insurances

Taro Minami is an Intensive Care Medicine provider in Pawtucket, Rhode Island. Dr. Minami is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Bullae, Emphysema, Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. David Rishikof
Intensive Care Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. David Rishikof
Intensive Care Medicine

ABA Somers MD LLC

115 Lincoln St Fl 2, 
Framingham, MA 
 (39.9 miles away)
508-383-8688
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Rishikof is an Intensive Care Medicine provider in Framingham, Massachusetts. Dr. Rishikof is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jabbour's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile